Hikal, Pfizer Sign Agreement for API Supply
ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer and Hikal signed a contract manufacturing agreement in which Hikal will supply active pharmaceutical ingredients.
Mumbai, India (Jan. 7)-Pfizer (New York) and Hikal signed a contract manufacturing agreement in which Hikal will supply active pharmaceutical ingredients. Terms of the agreement were not disclosed at press time.
“We are extremely pleased to be selected as a long-term contract manufacturer by Pfizer,” said Jai Hiremath, vice chairman and managing director of Hikal in a company statement. “This agreement will have a substantial impact on our pharmaceutical business in the coming years.”
“We look forward to working with Hikal, a respected contract manufacturing company and are delighted that they are able to contribute towards supply of APIs for Pfizer products,” said Peter Stevenson, vice-president, global contract manufacturing, procurement and Pfizer Center Source, Pfizer Inc., in a prepared statement.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
